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Objective: Normal cartilage is resistant to vascular invasion and anti-angiogenic protease inhibitors may
contribute to its avascular status.We hypothesized that dysregulated expression of four key anti-angiogenic
protease inhibitors may contribute to increased osteochondral vascularity in osteoarthritis (OA).
Design: Medial tibial plateaux from OA patients (n¼ 40) were compared with those from non-arthritic
controls collected post-mortem (PM, n¼ 10). Immunohistochemistry was performed for protease
inhibitors TIMP-1, TIMP-3, PAI-1 and SLPI and the pro-angiogenic factor vascular endothelial growth
factor (VEGF). Immunoreactivity in articular chondrocytes was scored. Chondropathy was measured as
a modiﬁed Mankin score, and osteochondral vascular density as number of channels crossing each mm of
tidemark. Non-parametric analyses were used for all data.
Results: All protease inhibitors and VEGF were localised to chondrocytes near the articular surface,
less often in the middle zone, and rarely to deep chondrocytes. Scores for VEGF, TIMP-1, TIMP-3, SLPI and
PAI-1 were all increased in OA compared with PM, and higher scores were associated with greater
chondropathy. Chondrocyte expression of VEGF was associated with higher osteochondral vascular
density (r¼ 0.32, P< 0.05), whereas protease inhibitors were not.
Conclusions: The resistance of normal articular cartilage to vascular invasion may be more due to its
matrix environment than ongoing protease inhibitor expression. Upregulation of protease inhibitors by
superﬁcial chondrocytes in OA may moderate the angiogenic effects of growth factors such as VEGF.
However, failure of deep chondrocytes to express anti-angiogenic protease inhibitors may permit
vascular invasion into the articular cartilage.
 2010 Osteoarthritis Research Society International. Published by Elsevier Ltd.
Open access under the Elsevier OA license. Introduction
Osteoarthritis (OA) is one of the leading causes of pain and
disability in aging populations. Current treatments improve
symptoms, but joint replacement surgery is still often required in
late-stage disease. Angiogenesis, the growth of new blood vessels
from pre-existing ones1, is characteristic of OA. New blood vessels
from the subchondral bone, breach the tidemark into the usually
avascular cartilage2. This osteochondral angiogenesis may poten-
tiate joint damage by stimulating ossiﬁcation in the articular
cartilage3–7. Angiogenesis also results in innervation of articularwth factor; EDTA, ethyl-
lex; DAPI, 40-60-diamidino-2-
teinase; PAI-1, plasminogen
proteinase inhibitor; PM,
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ternational. Published by Elsevier Lcartilage3, providing a possible source of pain in OA.We, and others,
have previous reported the range of osteochondral angiogenesis3,4,7
but the cause of this heterogeneity is not known.
The extent of angiogenesis results from a balance between
actions of angiogenic and anti-angiogenic factors. Angiogenic
factors such as vascular endothelial growth factor (VEGF) are
upregulated by chondrocytes8, and in subchondral bone in OA9.
Normal articular cartilage resists vascular invasion due to its matrix
composition, and also by producing diffusible angiogenesis inhib-
itors10. Matrix degradation is required to permit blood vessels to
penetrate cartilage, and protease producing cells line vascular
channels at the osteochondral junction11. Protease inhibitors
reduce angiogenesis by inhibiting this extracellular matrix degra-
dation, and the production by articular cartilage of tissue inhibitors
of metalloproteinases (TIMPs) is believed to contribute to its
resistance to vascular invasion12. Inhibitors of serine protease
inhibitorsmay also inhibit angiogenesis13, andmay be expressed by
chondrocytes14–17. TIMP-1, TIMP-3, and the serine protease inhibi-
tors secretory leukocyte proteinase inhibitor (SLPI) and plasmin-
ogen activator inhibitor (PAI)-1 are of particular interest due to
their speciﬁcities for proteases responsible for cartilage matrixtd. Open access under the Elsevier OA license. 
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anti-angiogenic activities13–17.
TIMP-1 is the dominant cartilage TIMP16, and can inhibit all
collagenases. TIMP-3 may have a particularly important role in
inhibition of cartilage degradation as it is the only TIMP capable of
inhibiting the A-Disintegrin And Metalloproteinase with Throm-
bospondin-like Repeats (ADAMTS)-4 and -5 enzymes18 which are
the major proteases responsible for degradation of aggrecan, the
main proteoglycan in cartilage. PAI-1 regulates activation of the
serine protease plasmin, which, in turn, contributes to cartilage
turnover by activating the pro-MMPs19. SLPI inhibits many cartilage
degrading proteases20, and may, in addition, reduce angiogenesis
by inhibiting endothelial cell migration13.
It has been suggested that osteoarthritic cartilage may lose the
ability to produce protease inhibitors21,22 and that the subsequent
imbalance between proteases and their inhibitors may contribute
to osteochondral vascularisation23. Other data, however, have
indicated that protease inhibitors may be upregulated in OA16,17.
Previous work has often focused on individual protease inhibitors,
often in animal models that may not adequately reﬂect human OA,
and without reference to osteochondral vascularity. We aimed to
address the hypothesis that altered protease inhibitor expression in
articular cartilage is associated with increased osteochondral
vascularity in human OA.
Methods
Patient recruitment and sample selection
Samples were collected from patients who fulﬁlled American
Rheumatism Association diagnostic criteria for OA24 and were
undergoing total knee replacement (TKR) surgery at King’s Mill
Hospital, Sutton-in-Ashﬁeld, UK. All patients had no additional
diagnosis of another rheumatic disease, did not display rheumatoid
nodules and had had no previous surgery or fracture to the joint.
Post-mortem (PM) knee samples were collected upon consent
from next-of-kin 25. PM samples were from patients who had no
history of arthritis or knee pain according to both next-of-kin and
medical records,werenotdiagnosedwithOAandhadnothadsurgery
or fracture to that joint. PM cases had no Heberden’s nodes, rheu-
matoid nodules or visible osteophytes.
All procedures were approved by Nottingham Research Ethics
Committee 1 (05/Q2403/24 and 05/Q2403/61).
Sample processing
All samples were processed on site at King’s Mill Hospital by an
experienced laboratory technician following standardised proce-
dures. Surgical samples were processed within 2 h of removal or
after storage at 4C overnight, and PM samples were immersed in
formalin immediately after removal. PM cases were stored at 4CTable I
Criteria for scoring immunoreactivity in articular cartilage
Score Criteria
TIMP-1 and TIMP-3 SLPI
0 No positive superﬁcial chondrocytes No positive superﬁcial
chondrocytes
1 Some, but fewer than 10% of superﬁcial
chondrocytes positive
Fewer than 50% of superﬁcial
chondrocytes positive
2 Thin layer (up to three cells deep)
of positive superﬁcial chondrocytes
50% or more of the superﬁcial
chondrocytes positive
3 Thick layer (>3 cells deep) of
positive superﬁcial chondrocytesprior to dissection, and median time from death to tissue ﬁxation
was 51 h (range 47–99 h). The middle one third (weightbearing
region) of mid-coronal sections from medial tibial plateaux were
ﬁxed in neutral buffered formalin overnight and then decalciﬁed in
10% ethylenediaminetetraacetic acid (EDTA) in 10 mM Tris buffer
(pH 6.95) at room temperature prior to wax embedding.
Sample selection
A cohort of 40 patients with OA and a range of osteochondral
vascular density suitable for correlational analysis was selected by
screening haematoxylin and eosin stained index sections from
medial tibial plateaux. Forty cases were selected with cartilage
present along at least 70% of the length of the tidemark, 20 without
tidemark breaching and 20 with high vascular densities at the
osteochondral junction.
In addition, 10 PM cases without tidemark breaching on index
sections were selected as a non-arthritic control group.
Histology
Polyclonal anti-TIMP-1 (1:200 dilution) was used with antigen
retrieval in 10 mM citrate buffer (pH 6) heated to 90C for 20 min.
Monoclonal anti-TIMP-3 (1:100 dilution) was used with antigen
retrieval in sodium phosphate/citrate buffer at 90C for 10 min.
Monoclonal anti-PAI-1 (diluted to 1:50) was used with antigen
retrieval in 0.1% trypsin in phosphate buffered saline (PBS) at 37C
for 30 min. Polyclonal anti-SLPI (1:200 dilution) and polyclonal
anti-VEGF (1:100 dilution) were used without antigen retrieval26.
After application of biotinylated secondary antibody visualization
was by avidin–biotin–peroxidase complex, developed with dia-
minobenzidine (DAB). All antibodies were diluted in 0.03% serum
from the host species of the secondary antibody (horse or goat) in
PBS, plus (except for SLPI immunohistochemistry) 0.05% bovine
serum albumin. Negative controls were incubated in diluent
without primary antibody. Immunohistochemistry for each antigen
was undertaken on sections from all cases within a single staining
run.
One section from each case was stained with haematoxylin and
eosin. Safranin-O staining with Fast-green FCF was carried out to
enable scoring of chondropathy as previously described3,4,27.
Analysis
Postero-anterior knee radiographs were allocated scores for
joint space narrowing and osteophytosis using a standardised line
atlas28. All histological scoring and visual analyseswere undertaken
blinded to disease group, using a Zeiss Axioscop-50 microscope,
under 10, 20 or 40 objective lens (Carl Zeiss Ltd, Welwyn
Garden City, UK). Where loss of section adhesion precluded scoring
for a case, actual numbers analysed are presented with the results.PAI-1 VEGF
No positive chondrocytes No positive superﬁcial chondrocytes
Positive chondrocytes in the
superﬁcial zone
Positive chondrocytes in the
superﬁcial zone
Positive chondrocytes in the
superﬁcial and intermediate zones
Positive chondrocytes in the
superﬁcial and intermediate zones
Positive chondrocytes in the superﬁcial,
intermediate and deep zones
R.E. Franse`s et al. / Osteoarthritis and Cartilage 18 (2010) 563–571 565Osteochondral vascular densities were determined as previ-
ously described3,4 as number of vascular channels terminating in
the non-calciﬁed cartilage divided by section length (measured by
digital caliper, Mitutoyo, Japan). Use of duplicate tissue sections
enabled analysis of vascular density as a continuous variable, as
all but four OA cases displayed tidemark breaching on one or
more sections. Safranin-O stained sections were scored for
chondropathy according to the modiﬁcation of Mankin’s method
excluding tidemark breaching4,27. This we refer to as chondrop-
athy score.
Scoring systems for abundance of immunoreactivity were
devised based on initial qualitative analysis (Table I). Samples were
scored for abundance of immunoreactivity in superﬁcial chon-
drocytes (TIMP-1, TIMP-3 and SLPI), or for the depth to whichFig. 1. Osteochondral vascularity and superﬁcial cartilage appearances in medial tibial platea
from a patient with OA (A), but not in one from a different patient with OA (C), nor from a PM
and D, respectively), chondrocyte depletion (B), or chondrocyte cloning (D, arrows). Cartilage
stain. Bar¼ 250 microns.immunoreactive chondrocytes were localised in articular cartilage
(PAI-1 and VEGF). All samples, except for PAI-1, were also cat-
egorised for presence or absence of immunoreactivity in deep
chondrocytes. For PAI-1, the deep chondrocytes contributed to the
overall cartilage scoring, and were not categorised separately.
Associations between protease inhibitor expression and disease
were explored by (1) comparing the extent of immunostaining
between OA and PM cases, and (2) by assessing the strength of any
associations between immunostaining and chondropathy scores.
As it was not possible to deﬁnitively exclude early OA from PM
cases (see above), initial correlation analyses combined PM and OA
groups, thereby giving a wide range of chondropathy scores, and
increased power to demonstrate statistical signiﬁcance. In order to
exclude the possibility that observed associations were mediatedux. Vascular channels (asterisks) breach the deepest tidemark (arrowheads) in a sample
case (E). Cartilage above the regions shown in A and C displays surface irregularity (B
above the region shown in E displays normal morphology (F). Haematoxylin and eosin
Fig. 2. Immunoreactivities for protease inhibitors and VEGF in superﬁcial chondrocytes in OA and PM. Photomicrographs represent OA (A, C, E, G, I) or PM (B, D, F, H, J) cases with
median scores for TIMP-1 (A, B), TIMP-3 (C, D), SLPI (E, F), PAI-1 (G, H) or VEGF (I, J). Each immunoreactivity is more abundant in OA than PM. Scale bar¼ 100 microns.
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Fig. 3. TIMP-1 (A, B), TIMP-3 (C, D), SLPI (E, F) and PAI-1 (G, H) scores were each higher in OA than in PM (A, C, E, G) and were each associated with greater chondropathy (B, D,
F, H). A, C, E and G: box and whisker plots. *P< 0.05, **P< 0.01 for differences between PM and OA. B, D, F and H: scatter plots of data from patients with OA (B) and PM
controls (:).
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Table II
Associations of immunoreactivities for protease inhibitors and VEGF with osteo-
chondral vascular density and chondropathy
Group(s) TIMP-1 TIMP-3 SLPI PAI-1 VEGF
Vascular density OAþ PM 0.11 0.10 0.10 0.28 0.32*
OA only 0.02 0.01 0.00 0.22 0.13
Chondropathy OAþ PM 0.67** 0.79** 0.55** 0.42** 0.66**
OA only 0.58** 0.79** 0.45** 0.24 0.61**
VEGF OAþ PM 0.62** 0.67** 0.57** 0.39** –
OA only 0.55** 0.67** 0.45** 0.25 –
Increased scores for each protease inhibitor and VEGF were associated with higher
chondropathy scores. Increased VEGF, but not protease inhibitors, was associated
with increased vascular density in the non-calciﬁed cartilage. Increased protease
inhibitor expression was associated with greater VEGF expression. Scoring criteria
for protease inhibitors and VEGF are given in Table I. Values are Spearman’s
rank correlation coefﬁcients for all cases (OAþ PM), or OA subgroup only (OA).
*P< 0.05 **P< 0.01 – signiﬁcant values are in bold.
R.E. Franse`s et al. / Osteoarthritis and Cartilage 18 (2010) 563–571568by disease group rather than chondropathy, we also undertook
secondary analyses excluding PM cases.
Statistics
Data were analysed using the Statistical Package for Social
Scientists (SPSS) version 14.0.1 (SPSS Inc, Chicago, IL, USA). Chi-
square and Mann–Whitney U tests were used to compare binomial
outcomes and scores between OA and PM. Associations between
variables are expressed as Spearman’s correlation coefﬁcients.
P< 0.05 was taken to indicate statistical signiﬁcance. Data are
presented as median (Interquartile Range (IQR)).
Materials
Polyclonal anti-TIMP-1 (Ab-6) was from Thermo Fisher Scien-
tiﬁc, Warrington, UK. Monoclonal anti-TIMP-3 (clone 136-13H4)
was from Merck, Nottingham, UK. Monoclonal anti-PAI-1 (3785)
was from Axis-Shield UK, Kimbolton, UK. Polyclonal anti-SLPI
(AF1274) was from R&D Systems, Abingdon, UK. Polyclonal anti-
VEGF (A20) was from Insight Biotechnology, London, UK. Secondary
biotinylated antibodies (BA-1000, BA2001 and BA9500) and the
Elite avidin–biotin–peroxidase complex were from Vector Labora-
tories, Peterborough, UK. Haemotoxylin and eosin were from Ray-
mond A Lamb, Eastbourne, UK. PBS was from VWR, Lutterworth,
UK. All other chemicals were from Sigma Aldrich, Poole, UK.
Results
Patient and sample details
OA cases (n¼ 40, median age 72 (IQR; 67–75) years, 21 females)
each reported knee pain for >5 years. Median joint space narrowing
score was 5 (IQR; 5 to 5) and osteophyte score was 8 (IQR; 8–10). PM
cases (n¼ 10, ﬁve females, median age 67 (IQR; 61–70) years) were
younger than OA cases (t¼2.4, P¼ 0.03), but age was not signiﬁ-
cantly associated with any of the scores or measurements in this
study. Sex distributionwas similar in PM andOA (c2¼ 0.30, P¼ 0.86).
Nine patients reported using regular oral non-steroidal anti-inﬂam-
matory agents, and two used glucosamine sulphate (all OA). Three
cases (two PM, one OA) had been taking systemic corticosteroids for
conditions unrelated to joint disease prior to tissue sampling.
OA samples displayed greater chondropathy (modiﬁed Mankin
scoremedian8 (IQR;6–10)) thanPMsamples (median4.5 (IQR;2.5–6),
Z¼3.48, P< 0.001) and displayed greater vascular density at the
osteochondral junction (OA:median 0.27 (IQR; 0.20–0.64) mm1; PM:
median 0.12 (IQR; 0.07–0.23) mm1; Z¼2.6, P¼ 0.01) (Fig. 1).TIMP-1
TIMP-1 positive chondrocytes were localised to the superﬁcial
zone of articular cartilage in all OA samples, but only occasionally in
PM controls [Fig. 2(A, B)]. TIMP-1 positive superﬁcial chondrocytes
were more abundant in OA than PM, (Z¼3.1, P¼ 0.002)
[Fig. 3(A)]. TIMP-1 expression in superﬁcial chondrocytes was
associated with greater chondropathy [Table II, Fig. 3(B)], but was
not associated with vascular density. Occasional chondrocytes in
the middle and deep zones displayed TIMP-1-immunoreactivity
[Fig. 4(A)]. The presence of TIMP-1 positive chondrocytes in the
deep zone did not differ between OA (22/39 cases) and PM (4/9
cases, c2¼ 0.42, P¼ 0.52). Vascular density did not differ between
samples with positive deep chondrocytes (median vascular density
0.24 (IQR; 0.09–0.57) mm1) and those without (median 0.28 (IQR;
0.19–0.57) mm1; Z¼0.45, P¼ 0.65).
TIMP-3
TIMP-3-immunoreactivity was occasionally detected in samples
from either disease group. TIMP-3-immunoreactivity was localised
within and around chondrocytes in the superﬁcial articular carti-
lage in OA and, less commonly in PM [Fig. 2(C, D)]. TIMP-3 positive
superﬁcial chondrocytes were more abundant in OA than PM
(Z¼2.6, P¼ 0.02) [Fig. 3(C)], and were associated with more
severe chondropathy [Table II, Fig. 3(D)] but not with vascular
density. TIMP-3-immunoreactivity in deep chondrocytes was only
occasionally observed [Fig. 4(B)], localised to regions with only
a thin layer of overlying cartilage, or where ﬁssures extended into
the deep cartilage. Presence of TIMP-3 in the deep chondrocytes did
not differ between OA (4/39 cases) and PM (1/9 cases, c2¼ 0.006,
P¼ 0.94). Vascular density did not differ between samples that
displayed TIMP-3 positive deep chondrocytes (median 0.22 (IQR;
0.10–1.39) mm1) and those that did not (median 0.26 (IQR; 0.14–
0.56) mm1; Z¼0.22, P¼ 0.83).
SLPI
SLPI was most commonly found in superﬁcial chondrocytes
[Fig. 2(E, F)], where there was signiﬁcant upregulation in OA
samples compared to PM (Z¼2.8, P¼ 0.007) [Fig. 3(E)]. SLPI-
positive superﬁcial chondrocytes were associated with greater
chondropathy [Table II, Fig. 3(F)] but not with vascular density.
Expression in the deeper zones of articular cartilage was less
extensive, and presence of positive cells in the deep zone [Fig. 4(C)]
did not differ between OA (27/39 cases) and PM (7/9 cases,
c2¼ 0.55, P¼ 0.76). Vascular density did not differ between
samples that displayed SLPI-positive deep chondrocytes (median
0.27 (IQR; 0.10–0.64) mm1) and those that did not (median 0.25
(IQR; 0.16–0.45) mm1; Z¼0.31, P¼ 0.75).PAI-1
Most samples displayed PAI-1 immunoreactive chondrocytes near
the surface of the articular cartilage [Fig. 2(G, H)], with expression
decreasing towards the tidemark, but sometimes extending to include
deep chondrocytes [Fig. 4(D)]. The depth of articular cartilage inwhich
PAI-1 positive cells were identiﬁed ranged from 1 or 2 cells thick to all
chondrocytes being positive down to the tidemark. PAI-1 positive
chondrocyteswereobserved indeeper regionsof thearticularcartilage
inOAthanPM(Z¼2.8,P¼ 0.007) [Fig.3(G)]. Chondrocyteexpression
of PAI-1was associatedwith greater chondropathy [Table II, Fig. 3(H)],
but association with vascular density did not reach statistical signiﬁ-
cance (r¼ 0.28, P¼ 0.054).
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Fig. 5. Associations between VEGF, vascular invasion and chondropathy. Scatter plots
showing that scores of VEGF in superﬁcial chondrocytes increased with increasing (A)
chondropathy and (B) density of vascular channels breaching the tidemark. OA (B) and
PM controls (:).
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Most samples displayed VEGF-positive chondrocytes near the
surface of the articular cartilage [Fig. 2(I, J)]. The layer of VEGF-
positive chondrocytes sometimes extended into the intermediate
zone of the cartilage, and isolated VEGF-positive chondrocytes or
chondrocyte clusters were occasionally found in the deep zone
and the calciﬁed cartilage [Fig. 4(E)]. VEGF-positive chondrocytes
were observed in deeper regions of the articular cartilage in OA
(median score 1 (IQR; 1–2)) than PM (median 0 (IQR; 0–1))
(Z¼3.7, P< 0.001). Chondrocyte expression of VEGF was asso-
ciated with greater chondropathy and with higher vascular density
in the non-calciﬁed cartilage (Table II, Fig. 5). The depth to which
VEGF-positive chondrocytes were localised was associated with
greater expression of each protease inhibitor (Table II). Vascular
density did not differ between samples that displayed VEGF-
positive deep chondrocytes (median 0.25 (IQR; 0.17–0.88) mm1)
and those that did not (median 0.24 (IQR 0.11–0.52) mm1;
Z¼0.69, P¼ 0.49).Fig. 4. Chondrocytes in the deep and calciﬁed zones of cartilage may display immu-
noreactivities for protease inhibitors and VEGF. (A) TIMP-1 positive chondrocytes in
the non-calciﬁed cartilage close to the tidemark in a patient with OA. (B) TIMP-3
positive hypertrophic chondrocytes in the non-calciﬁed cartilage, just above the
tidemark in a patient with OA. (C) SLPI-positive chondrocytes in the deep zone of
the non-calciﬁed cartilage of a patient with OA. (D) PAI-1 positive chondrocytes in the
deep zone of the non-calciﬁed cartilage of a patient with OA. (E) VEGF-positive
chondrocytes in the calciﬁed cartilage of a patient with OA. CC¼ calciﬁed cartilage.
Scale bars¼ 100 microns.
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We have shown that osteoarthritic articular cartilage contains
chondrocytes that display increased expression of the angiogenic
factor VEGF, and also of a variety of protease inhibitors that are
known to have anti-angiogenic activity. Chondrocyte expression
both of angiogenic and anti-angiogenic factors is greater in cases
with more severe osteoarthritic structural change. Although
superﬁcial chondrocytes display a clear ability to express anti-
angiogenic protease inhibitors in OA, those in the deep zone, the
site of osteochondral angiogenesis, did not demonstrate protease
inhibitor upregulation. When angiogenic stimuli are increased in
OA, this apparent deﬁciency of deep chondrocytes may permit
vascular invasion into the articular cartilage.
Our ﬁndings provide immunolocalisation data that extend
previous studies on TIMP-1 and PAI-1 mRNA upregulation by
superﬁcial chondrocytes in human OA29. We show similar upre-
gulation of two further anti-angiogenic protease inhibitors in OA,
TIMP-3 and SLPI, with comparable expression patterns to TIMP-1.
Our data do not support a role for these protease inhibitors in
maintaining the avascular status of normal cartilage, as they were
largely absent from PM cases. Constitutive factors within the
normal cartilage matrix may be more important in maintaining its
avascularity than is expression of anti-angiogenic protease inhibi-
tors by chondrocytes. Protease inhibitor upregulation alongside
increased angiogenic factor expression however may moderate
osteochondral angiogenesis, for example by inhibiting receptor
shedding or growth factor activation.
The tidemark in normal cartilage provides a barrier to macro-
molecule diffusion and mass transport. Chondropathy and tide-
mark breaching by vascular channels in OA may, however, permit
growth factors such as VEGF from superﬁcial cartilage to access the
osteochondral junction. Stimulation of osteochondral angiogenesis
by VEGF produced by superﬁcial chondrocytes may explain our
observed association between VEGF expression and osteochondral
vascular density. Such an angiogenic drive from superﬁcial chon-
drocytes would be additional to that from growth factors (including
VEGF) produced within the subchondral bone marrow spaces9,30,31.
By contrast, osteochondral vascular densities in OA were not
associated with protease inhibitor expression, indicating that
protease inhibitors generated by superﬁcial chondrocytes may not
gain access to the deeper articular cartilage in concentrations that
can prevent vascular invasion, particularly in the context of the
increased angiogenic drive of OA.
Previous studies of VEGF expression by articular chondrocytes
have not demonstrated associations with osteochondral angio-
genesis8, and the relatively weak association in the current study
(R¼ 0.32) was only observed when OA and PM groups were
combined. Chondrocyte-derived VEGF may play roles other than
supporting angiogenesis, and has been reported to increase MMP
expression in immortalized chondrocytes32. We observed a coor-
dinated upregulation of protease inhibitors and VEGF. VEGF may
therefore contribute to OA severity both as an angiogenic factor and
as a regulator of matrix turnover.
Our study was limited by a number of factors. Deﬁnition of
a normal control group is difﬁcult for a condition such as OA, where
onset may be insidious, and pathological change may occur in the
absence of symptoms. PM cases provide a source of non-arthritic
tissues, but may display macroscopic or microscopic changes
consistentwithOAeven in theabsenceof symptomsprior todeath33.
We attempted to avoid inclusion of cases with OA in the PM group,
based on clinical history,macroscopic andmicroscopic appearances,
but cannot exclude the possibility that some patients had early or
mild OA. We also cannot exclude the possibility that protease anti-
genicity declined in PM samples prior to tissue harvesting. However,immunoreactivities in deep chondrocytes were similar in both PM
and OA cases, increased protease immunoreactivities were associ-
ated with greater chondropathy within OA samples (Table II), and
extent of immunoreactivity was not signiﬁcantly associated with
time from death to tissue processing (data not shown).
We used a targeted approach to identify protease inhibitors that
may be downregulated in OA, focusing on those forwhich therewas
prior evidence of expression by chondrocytes or ability to inhibit
angiogenesis. Future work should address changes in cartilage
matrix and expression of other important anti-angiogenic factors.
Osteochondral angiogenesis is accompanied by sensory nerve
growth3. Inhibition of osteochondral angiogenesis may therefore
improve symptoms by structural disease modiﬁcation. It may be
unnecessary for a disease modifying drug to prevent all changes of
chondropathy, if preventing the structural changes leading to pain
can be achieved alone. We speculate that facilitating the anti-
angiogenic effects of protease inhibitors may achieve such a goal.
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